Evidence map›Paper›PMID 35682999›Full record

ArticleInternational journal of molecular sciences2022

Targeting PIK3CA Actionable Mutations in the Circulome: A Proof of Concept in Metastatic Breast Cancer.

Barbara Cardinali, Giuseppa De Luca, Roberta Tasso, Simona Coco, Anna Garuti, Giulia Buzzatti, Andrea Sciutto, Luca Arecco, Federico Villa, Franca Carli and 4 more

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Network approach in liquidomics landscape.Journal of experimental & clinical cancer research : CR · 2023
    Review
  6. Omics-Based Investigations of Breast Cancer.Molecules (Basel, Switzerland) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Barbara CardinaliClinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, 10-16132 Genova, Italy.
Giuseppa De LucaMolecular Diagnostic Unit, IRCCS Ospedale Policlinico San Martino, 10-16132 Genova, Italy.
Roberta TassoDepartment of Experimental Medicine (DIMES), University of Genova, 5-16126 Genova, Italy.
Simona CocoLung Cancer Unit, IRCCS Ospedale Policlinico San Martino, 10-16132 Genova, Italy.ORCID 0000-0002-5296-4325
Anna GarutiClinica Oncologia Medica ad Indirizzo Oncologico, IRCCS Ospedale Policlinico San Martino, 10-16132 Genova, Italy.
Giulia BuzzattiOncologia Medica 2, IRCCS Ospedale Policlinico San Martino, 10-16132 Genova, Italy.
Andrea SciuttoClinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, 10-16132 Genova, Italy.
Luca AreccoClinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, 10-16132 Genova, Italy.ORCID 0000-0002-3818-0364
Federico VillaMolecular Oncology and Angiogenesis Unit, IRCCS Ospedale Policlinico San Martino, 10-16132 Genova, Italy.
Franca CarliSurgical Pathology Unit, IRCCS Ospedale Policlinico San Martino, 10-16132 Genova, Italy.
Daniele ReverberiMolecular Pathology Unit, IRCCS Ospedale Policlinico San Martino, 10-16132 Genova, Italy.
Rodolfo QuartoDepartment of Experimental Medicine (DIMES), University of Genova, 5-16126 Genova, Italy.ORCID 0000-0002-1146-894X
Mariella DonoMolecular Diagnostic Unit, IRCCS Ospedale Policlinico San Martino, 10-16132 Genova, Italy.ORCID 0000-0003-1280-0278
Lucia Del MastroClinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, 10-16132 Genova, Italy.ORCID 0000-0002-9546-5841
Ospedale Policlinico San Martino · ITUniversity of Genoa · IT

Funding

Italian Association for Cancer Research IG 20760Italian Ministry of Health 5X1000 Funds 2015-2016; Ricerca Corrente
6 · The paper itself

Abstract

The study of circulating cancer-derived components (circulome) is considered the new frontier of liquid biopsy. Despite the recognized role of circulome biomarkers, their comparative molecular profiling is not yet routine. In advanced breast cancer (BC), approximately 40% of hormone-receptor-positive, HER2-negative BC cases harbor druggable

Indexed as

Breast NeoplasmsCirculating Tumor DNANeoplastic Cells, CirculatingBiomarkers, TumorClass I Phosphatidylinositol 3-KinasesEpithelial Cell Adhesion MoleculeFemaleHumansMutationPilot ProjectsBiomarkers, TumorCirculating Tumor DNAClass I Phosphatidylinositol 3-KinasesEpithelial Cell Adhesion MoleculePIK3CA protein, humanbreast cancercirculating tumor cellscirculating tumor DNAextracellular vesiclesliquid biopsyPIK3CA mutations

Identifiers

PMID35682999
PMCPMC9181240
OpenAlexW4281833873

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.